Glaucoma Eye Articles & Analysis
23 news found
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. ...
To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of glaucoma. Glaucoma is a serious ...
The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. But when it comes to detecting severe conditions like glaucoma and macular degeneration, the naked eye’s powers are limited. ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. ...
Recent Business Highlights Generated first quarter 2022 total revenue of $14.9 million, an increase of 72% compared to the prior year period Increased the number of facilities ordering the OMNI® Surgical System from 760 in the fourth quarter of 2021 to 811 in the first quarter of 2022, and the installed base of TearCare® facilities from 562 on December 31, 2021 to 635 on March 31, ...
Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...
The TRIDENT study is a prospective, randomized, multicenter, comparative trial evaluating the safety and effectiveness outcomes, including IOP reduction, for pseudophakic eyes (eyes which had previously undergone cataract surgery) in three study arms: (1) canaloplasty alone using the OMNI Surgical System, (2) sequential canaloplasty followed by trabeculotomy ...
I look forward to contributing toward its next stages of growth as they expand their existing businesses in glaucoma and dry eye and develop their robust pipeline of innovations in ophthalmology and ...
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of ...
IOP-Connect is based on an implantable intra-ocular pressure (IOP) sensor platform smaller than a grain of rice, that for the first time is expected to provide continuous and autonomous long-term IOP data from inside a glaucoma patient’s eye. The funding follows IOP-Connect’s FDA Breakthrough Device Program (BDP) designation in 2020 and covers 2 ...
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces its new corporate branding and new website. ...
This data aligns with prior secondary, independent patient research from Johns Hopkins University showing that 56% – 59% of glaucoma patients would accept contact lens to treat their disease if they made glaucoma surgery unnecessary or were more effective than eye drops. ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ...
The Latanoprost FA SR Ocular Implant is designed to substitute for daily drop therapy by providing sustained treatment from a single implant administration over a six-month period to treat glaucoma. Up to 46 percent of patients do not remember to use their eye drops or administer them poorly. Adherence to daily drop therapy is critical to slow progression of ...
She has previously held board membership seats at The Glaucoma Foundation and the ARVO Foundation for Eye Research. She is also a former board member of and current advisor to Ophthalmic World Leaders (OWL), Advancing Diversity in Leadership, which aims to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care. ...
Leo Lens expanded its SAB with four eye care practitioners who are highly experienced in the glaucoma field as the company prepares for its first human clinical trial with its lead asset to treat glaucoma and ocular hypertension. ...
LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clinical research organization to oversee the initial human clinical trial, secured the ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever, four-year follow-up data for a MIGS device in an FDA pivotal trial. ...